Compare iShares China Large-Cap ETF (FXI) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Oscar Health Inc — how do they compare? iShares China Large-Cap ETF trades at $35.18, while Oscar Health Inc trades at $29.54 (market cap $8.63B). The key difference: Oscar Health Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | OSCR | |
|---|---|---|
52-Week High | $41.75 | $32.18 |
52-Week Low | $31.59 | $10.85 |
Market Cap | — | $8.63B |
Sector | — | Health |
Enterprise Value | — | $4.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $35.23, down 3.45% on the day amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, while oscillators remain neutral. The ETF benefits from China's export strength and AI-driven manufacturing rebound, though financial ratios are currently unavailable. Recent news highlights China's 23% July export growth and ongoing infrastructure investments to support economic stability.
FXI offers exposure to China's large-cap recovery with state-backed stimulus and AI export growth as key catalysts. However, geopolitical tensions and US-China tech restrictions pose significant risks. The ETF's heavy financial sector weighting provides stability but limits pure tech exposure, requiring careful monitoring of China's economic policies and global trade dynamics.
Oscar Health (OSCR) trades at $29.11, up 5.2% with strong recent earnings momentum, beating estimates in Q1 and Q2 2026. The stock shows bearish technical signals but benefits from record profitability and raised 2026 guidance. Revenue surged 70% to $4.9 billion in H1 2026, with net income turning positive at $551 million versus a 2025 loss. Valuation remains attractive with P/S of 0.53, suggesting potential undervaluation versus sector peers.
Outlook is positive given membership growth and cost discipline, but risks include medical cost volatility and competitive pressures. Analyst consensus price target of $32.50 implies 12% upside, though technical resistance near $30 may limit near-term gains. Execution on guidance and sustained margin expansion are key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
